S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:ARQT

Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis

$10.28
-0.13 (-1.25%)
(As of 02/29/2024 ET)
Today's Range
$9.33
$10.57
50-Day Range
$2.60
$10.63
52-Week Range
$1.76
$17.57
Volume
12.49 million shs
Average Volume
5.67 million shs
Market Capitalization
$970.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.56

Arcutis Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
158.3% Upside
$26.56 Price Target
Short Interest
Bearish
17.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of Arcutis Biotherapeutics in the last 14 days
Based on 30 Articles This Week
Insider Trading
Selling Shares
$4,690 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.65) to ($1.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

613th out of 958 stocks

Pharmaceutical Preparations Industry

278th out of 432 stocks


ARQT stock logo

About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Stock Price History

ARQT Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Arcutis Announces Pricing of $150 Million Public Offering
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Arcutis Announces Proposed Public Offering
Breaking Down Arcutis Biotherapeutics: 4 Analysts Share Their Views
Arcutis Biotherapeutics (ARQT) Gets a Hold from JonesTrading
Q4 2023 Arcutis Biotherapeutics Inc Earnings Call
See More Headlines
Receive ARQT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
2/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARQT
Fax
N/A
Employees
268
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$26.56
High Stock Price Target
$50.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+158.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-311,460,000.00
Net Margins
-439.79%
Pretax Margin
-540.06%

Debt

Sales & Book Value

Annual Sales
$59.61 million
Book Value
$3.44 per share

Miscellaneous

Free Float
74,845,000
Market Cap
$970.23 million
Optionable
Optionable
Beta
0.96

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Todd Franklin Watanabe M.A.Mr. Todd Franklin Watanabe M.A. (Age 56)
    President, CEO & Director
    Comp: $1.01M
  • Dr. Bhaskar Chaudhuri Ph.D. (Age 69)
    Co-Founder & Independent Director
    Comp: $59.67k
  • Mr. Masaru Matsuda Esq. (Age 53)
    J.D., Senior VP, General Counsel & Corporate Secretary
    Comp: $626.22k
  • Dr. Patrick E. Burnett M.D. (Age 52)
    Ph.D., Senior VP & Chief Medical Officer
    Comp: $689.95k
  • Mr. John W. Smither CPA (Age 71)
    Interim CFO & Principal Accounting Officer
    Comp: $410.75k
  • Mr. Rajvir Madan
    Chief Digital & Technology Officer
  • Mr. Eric McIntyre
    Head of Investor Relations
  • Ms. Courtney Barton (Age 41)
    VP and Chief Compliance Officer & Privacy Officer
  • Ms. Amanda Sheldon
    Head of Corporate Communications
  • Ms. Ayisha Jeter
    Head of Marketing & Market Access














ARQT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcutis Biotherapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARQT shares.
View ARQT analyst ratings
or view top-rated stocks.

What is Arcutis Biotherapeutics' stock price target for 2024?

9 analysts have issued twelve-month price objectives for Arcutis Biotherapeutics' shares. Their ARQT share price targets range from $8.00 to $50.00. On average, they predict the company's share price to reach $26.56 in the next year. This suggests a possible upside of 158.3% from the stock's current price.
View analysts price targets for ARQT
or view top-rated stocks among Wall Street analysts.

How have ARQT shares performed in 2024?

Arcutis Biotherapeutics' stock was trading at $3.23 on January 1st, 2024. Since then, ARQT shares have increased by 218.3% and is now trading at $10.28.
View the best growth stocks for 2024 here
.

When is Arcutis Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARQT earnings forecast
.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) issued its earnings results on Tuesday, February, 27th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.08. The company earned $13.53 million during the quarter, compared to analysts' expectations of $11.78 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 294.59% and a negative net margin of 439.79%. During the same quarter in the previous year, the business posted ($1.18) earnings per share.

What ETF holds Arcutis Biotherapeutics' stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 10,172 shares of ARQT stock, representing 0.89% of its portfolio.

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

When did Arcutis Biotherapeutics IPO?

(ARQT) raised $125 million in an initial public offering on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

Who are Arcutis Biotherapeutics' major shareholders?

Arcutis Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Jennison Associates LLC (9.61%), Frazier Life Sciences Management L.P. (9.29%), Rubric Capital Management LP (7.04%), Vanguard Group Inc. (5.19%), Franklin Resources Inc. (4.93%) and Vestal Point Capital LP (2.86%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends
.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARQT) was last updated on 3/1/2024 by MarketBeat.com Staff